Glucocorticoids in the treatment of glomerular diseases: pitfalls and pearls

C Ponticelli, F Locatelli - Clinical Journal of the American Society …, 2018 - journals.lww.com
Glucocorticoids exert anti-inflammatory and immunosuppressive activities by genomic and
nongenomic effects. The classic genomic effects are mediated by cytosolic glucocorticoid …

Therapies for membranous nephropathy: a tale from the old and new millennia

F Scolari, F Alberici, F Mescia, E Delbarba… - Frontiers in …, 2022 - frontiersin.org
Primary Membranous Nephropathy (PMN) is the most frequent cause of nephrotic syndrome
in adults. If untreated, PMN can lead to end-stage renal disease; moreover, affected patients …

Membranous nephropathy: quantifying remission duration on outcome

DC Cattran, ED Kim, H Reich… - Journal of the …, 2017 - journals.lww.com
Although change in proteinuria has been proposed as a surrogate for long-term prognosis in
membranous nephropathy (MGN), variability in proteinuria levels and lag between these …

Complete and partial remission as surrogate end points in membranous nephropathy

A Thompson, DC Cattran, M Blank… - Journal of the American …, 2015 - journals.lww.com
Absent a remission of proteinuria, primary membranous nephropathy (MN) can lead to
ESRD over many years. Therefore, use of an earlier end point could facilitate the conduct of …

The management of membranous nephropathy—an update

F Caravaca-Fontán… - Nephrology Dialysis …, 2022 - academic.oup.com
In recent decades, several important advances have taken place in the understanding of the
pathogenesis underlying membranous nephropathy (MN) that have sparked renewed …

[HTML][HTML] Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and rituximab

M Waldman, LH Beck Jr, M Braun, K Wilkins… - Kidney international …, 2016 - Elsevier
Introduction There is broad consensus that high-grade basal proteinuria and failure to
achieve remission of proteinuria are key determinants of adverse renal prognosis in patients …

A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus–Rituximab versus steroids plus …

J Rojas-Rivera, G Fernández-Juárez… - Clinical kidney …, 2015 - academic.oup.com
Background Patients with primary membranous nephropathy (MN) and persistent nephrotic
syndrome have a high risk of progression to end-stage renal disease. The Ponticelli protocol …

Pharmacological treatment of primary membranous nephropathy in 2016

AE van de Logt, JM Hofstra… - Expert review of clinical …, 2016 - Taylor & Francis
Introduction: Therapy in patients with primary membranous nephropathy is debated. The
discovery of anti-PLA2R antibodies provides opportunities for new treatment strategies …

Revisiting immunological and clinical aspects of membranous nephropathy

I Nieto-Gañán, I Iturrieta-Zuazo, C Rita… - Clinical …, 2022 - Elsevier
Idiopathic or primary membranous nephropathy (IMN) is one of the most frequent causes of
nephrotic syndrome in adults and the elderly. It is characterized by a thickening of the wall of …

New ways of understanding membranous nephropathy

H Trujillo, M Alonso, M Praga - Nephron, 2020 - karger.com
Background: In the last decade, great advances have been made in the field of membranous
nephropathy (MN). The autoimmune nature of the disease has been confirmed with the …